333361-49-2

Basic information

• Product Name: (5-broMo-2-chloro-phenyl)-(4-ethoxy-phenyl)-Methanone
• Synonyms: (5-broMo-2-chloro-phenyl)-(4-Methoxyl-phenyl)-Methanone;(5-Bromo-2-chlorophenyl)(4-methoxyphenyl)-methanone
• CAS NO: 333361-49-2
• Molecular Formula: C₁₄H₁₀BrClO₂
• Molecular Weight: 325.585
• Mol File: 333361-49-2.mol
• Article Data: 30

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• Solubility: Dichloromethane; Ethyl Acetate
• CAS DataBase Reference: (5-broMo-2-chloro-phenyl)-(4-ethoxy-phenyl)-Methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (5-broMo-2-chloro-phenyl)-(4-ethoxy-phenyl)-Methanone(333361-49-2)
• EPA Substance Registry System: (5-broMo-2-chloro-phenyl)-(4-ethoxy-phenyl)-Methanone(333361-49-2)

Safety Data

• Hazardous Substances Data: 333361-49-2(Hazardous Substances Data)

Usage

Description

(5-Bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone is an organic compound that serves as an intermediate in the synthesis of pharmaceuticals. It is characterized by the presence of a bromo and chloro substituent on a phenyl ring, as well as an ethoxy group on another phenyl ring, all connected through a methanone linkage.

Uses

Used in Pharmaceutical Industry:
(5-Bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone is used as a key intermediate in the synthesis of Dapagliflozin-D5 (D185372), a labelled analogue of Dapagliflozin (D185370). Dapagliflozin is a selective sodium-glucose cotransporter-2 (SGLT2) inhibitor that reduces renal glucose reabsorption, making it an effective treatment for patients with type 2 diabetes. (5-broMo-2-chloro-phenyl)-(4-ethoxy-phenyl)-Methanone plays a crucial role in the development of this medication, contributing to the management of blood sugar levels and improving the overall quality of life for individuals living with diabetes.

Upstream product

• 100-66-3 methoxybenzene 
• 21900-52-7 5-bromo-2-chloro-benzoyl chloride 
• 21739-92-4 5-bromo-2-chlorobenzoic acid 

Downstream Products

• 333361-51-6 4-bromo-1-chloro-2-(4-methoxybenzyl)benzene 
• 461432-26-8 dapagliflozin 
• 1204219-40-8 4-((5-bromo-2-chlorophenyl)methyl-d2)phenol 
• 864070-19-9 [4-(5-bromo-2-chloro-benzyl)-phenoxy]-tert-butyl-dimethyl-silane 
• 1548877-02-6 (4-((5-bromo-2-chlorophenyl)methyl-d2)phenoxy)(tertbutyl)dimethylsilane 
• 1204220-63-2 (2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 1204220-65-4 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-2-d-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1204221-17-9 (2S,3R,4R,5S,6R)-2-(4-chloro-3-((4-hydroxyphenyl)methyld2)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 864070-37-1 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1204219-80-6 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(ethoxy-d5)benzyl)-phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1204219-68-0 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(ethoxy-1,1-d2)benzyl)-phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1204219-27-1 (2R,3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-2-d-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1204219-36-2 (2S,3R,4R,5S,6R)-2-(4-chloro-3-((4-ethoxyphenyl)methyl-d2)-phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1204219-51-1 (2S,3R,4R,5S,6R)-2-(4-chloro-3-((4-(ethoxy-d5)phenyl)-methyl-d2)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 

Relevant articles and documents

GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS

The present invention is directed to glucopyranose derivatives of formula (I), pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.

Combined catalyst for use in specific Friedel-Crafts reactions

The invention provides an application of a ferric trichloride and indium trichloride combined catalyst in a specific Friedel-Crafts reaction, more specifically, the invention provides an application of a ferric trichloride and indium trichloride combined Lewis acid catalyst in preparation of a key intermediate of empagliflozin, dapagliflozin and canagliflozin drugs. Compared with the prior art, the ferric trichloride and indium trichloride combined catalyst provided by the invention can greatly reduce the use of inorganic salt in the preparation process of the key intermediate of the empagliflozin, dapagliflozin and canagliflozin drugs, and obviously reduce the emission of waste water, waste gases and waste residues; and the ferric trichloride and indium trichloride combined catalyst can significantly improve the selectivity of para-position products in the preparation process of the key intermediate of the empagliflozin, dapagliflozin and canagliflozin drugs, can remarkably improve the quality and the yield of a target product, and remarkably reduce the process cost.

Carbon glucoside sodium glucose transport protein body 2 inhibitor

The invention relates to a carbon glucoside sodium glucose transport protein body 2 inhibitor, a preparation method and an application of the inhibitor. The carbon glucoside sodium glucose transport protein body 2 inhibitor has a structure as shown in general formula (I) as shown in the specification.